Prostate Cancer
Stampede Systemic Therapy in Advancing or Metastatic Prostate cancer – Evaluation of Drug Efficacy (information also available at Antrim and Craigavon Hospitals)
UKGPC UK Genetics Prostate Cancer Study (also available in Altnagelvin, Antrim, Craigavon and Ulster Hospitals)
Rapper Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy (only available for patients who have participated in RADICALS or CHHIP study or radical radiotherapy in the STAMPEDE study) (also available at Altnagelvin)
PROSPER A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
TOPARP Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer
PACE International randomised study of laparoscopic prostatectomy vs stereotactic body radiotherapy (SBRT) and conventionally fractionated radiotherapy vs SBRT for early stage organ-confined prostate cancer
CASPIR Calcifications as an alternative to surgically implanted fiducial markers for prostate image guided radiotherapy (CASPIR): A prospective feasibility study
ADRRAD Neo-adjuvant Androgen Deprivation Therapy, Pelvic Radiotherapy and RADium-223 for new presentation T1-4 N0/1 M1B adenocarcinoma of prostate
LAPCD Life After Prostate Cancer Diagnosis (also available at Altnagelvin, Craigavon and the Ulster Hospital)
SPORT High-Risk Trial A Randomised Feasibility Study Evaluating Stereotactic Prostate Radio Therapy In High-Risk Localised Prostate Cancer With Or Without Elective Nodal Irradiation
Immune gene expression and tumour microenvironment in prostate cancer How does radiotherapy affect immune gene expression and the tumour microenvironment in men with localised prostate cancer?
RE-AKT A Randomised Phase II Study Of Enzalutamide (MDV3100) In Combination With AZD5363 In Patients With Metastatic Castration-Resistant Prostate Cancer
